Ionis Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Ionis Pharmaceuticals, Inc. (IONS) reported Net Income (Loss) Available to Common Stockholders, Diluted of $127.56 million for the 6-month period ending 2025-12-31, per its 10-Q filed 2025-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $127.56M.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was $226.21M.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2019-12-31 was $196.49M, a 40.54% decline year-over-year.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2019-09-30 was $26.16M.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2019 was $290.95M, a 5.09% increase from fiscal 2018.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2018 was $276.87M, a 1373.33% increase from fiscal 2017.
- Ionis Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2017 was $18.79M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $127.56M 10-Q · filed 2025-07-30 | ||||||
| 2025-06-30 | $127.56M 10-Q · filed 2026-07-29 | ||||||
| 2021-12-31 | $226.21M 10-K · filed 2023-02-22 | ||||||
| 2019-12-31 | $196.49M 10-K · filed 2021-02-24 | $222.64M derived: sum of 2 quarters · filed 2021-02-24 | $221.73M derived: sum of 3 quarters · filed 2021-02-24 | $290.95M 10-K · filed 2022-02-25 | $296.56M 10-K · filed 2020-03-02 | ||
| 2019-09-30 | $26.16M 10-Q · filed 2020-11-04 | $25.24M derived: sum of 2 quarters · filed 2020-11-04 | $112.76M 10-Q · filed 2020-11-04 | $443.23M derived: sum of 4 quarters · filed 2020-11-04 | |||
| 2019-06-30 | -$915.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $86.63M 10-Q · filed 2020-08-05 | $417.07M derived: sum of 3 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $87.54M 10-Q · filed 2020-05-06 | $417.98M derived: sum of 2 quarters · filed 2020-05-06 | |||||
| 2018-12-31 | $330.44M 10-K · filed 2020-03-02 | $276.87M 10-K · filed 2021-02-24 | |||||
| 2017-12-31 | $2.72M 10-K · filed 2018-02-28 | $13.16M derived: sum of 2 quarters · filed 2018-11-06 | $10.07M derived: sum of 3 quarters · filed 2018-11-06 | $18.79M 10-K · filed 2020-03-02 | $9.66M 10-K · filed 2018-02-28 | ||
| 2017-09-30 | $10.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $7.36M derived: sum of 2 quarters · filed 2018-11-06 | $16.32M 10-Q · filed 2018-11-06 | $2.89M 10-Q · filed 2017-11-07 | $42.19M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-06-30 | -$3.09M derived: 10-Q 6 month − 10-K 3 month · filed 2018-08-07 | $5.88M 10-Q · filed 2018-08-07 | $31.74M derived: sum of 3 quarters · filed 2019-03-01 | $39.09M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $8.96M 10-K · filed 2019-03-01 | $3.47M 10-Q · filed 2017-05-09 | $34.83M derived: sum of 2 quarters · filed 2019-03-01 | $42.18M derived: sum of 3 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $25.86M 10-K · filed 2018-02-28 | $33.22M derived: sum of 2 quarters · filed 2018-02-28 | |||||
| 2016-09-30 | $7.35M 10-K · filed 2018-02-28 | ||||||
| 2015-06-30 | $36.70M 10-K · filed 2017-03-01 | $18.93M 10-Q · filed 2016-08-09 | |||||
| 2014-12-31 | $31.05M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |